However, other studies have shown that the p53 status does not alter tumor cell sensitivity to PLK1 inhibitors (Moison et al., 2019), and that PLK1 inhibitors selectively target cells with mutant p53 rather than wild-type p53 cells (Li Y. et al., 2020). Here, PLK1 is linked to neoplasm.